To include your compound in the COVID-19 Resource Center, submit it here.

Critical Outcomes expands Phase I COTI-2 study to HNSCC

Critical Outcome Technologies Inc. (TSX-V:COT; OTCQB:COTQF) expanded an open-label, U.S. Phase I trial evaluating oral COTI-2 in

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE